対象文献

19件該当しました。

1. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
   Long GV, et al.: Lancet 386（9992）: 444-51（2015）
2. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.
   Hauschild A, et al.: Lancet 380（9839）: 358-65（2012）
3. Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma.
   Flaherty KT, et al.: N Engl J Med 367（2）: 107-14（2012）
4. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
   Flaherty KT, et al.: N Engl J Med 367 (18)：1694-703（2012）
5. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor.
   Johnson DB, et al.: J Clin Oncol 32 (33) : 3697-704（2014）
6. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose- escalation trial.
   Falchook GS, et al.: Lancet 379 (9829) : 1893-901 (2012)
7. Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib(GSK2118436) in Patients With Metastatic Melanoma.
   Ascierto PA, et al.: J Clin Oncol 31 (26) : 3205-11 (2013)
8. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
   Long GV, et al.: Lancet Oncol 13 (11) : 1087-95 (2012)
9. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
   Falchook GS, et al.: Lancet Oncol 13(8): 782?9 (2012)
10. Phase II study of the MEK1/MEK2 inhibitor Trametinib in　patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a　BRAF inhibitor.
    Kim KB, et al.: J Clin Oncol 31(4): 482-9（2013）
11. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma.
    Schadendorf D,et al.: Eur J Cancer 51(7):833-40 (2015)
12. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-l
    Grob JJ,et al.: Lancet Oncol 16(13):1389-98 （2015）
13. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
    Sakaizawa K, et al.: J Dermatol Sci 80(1):33-7（2015）
14. Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma.
    Carlino MS, et al.: Mol Cancer Ther 12(7):1332-42（2013）
15. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
    Wagle N,et al.: Cancer Discov 4(1):61-8（2014）
16. Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma.
    Lee CI, et al.:Melanoma Res 24(5):468-74（2014）
17. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial.
    Menzies AM, et al.: Ann Oncol 26 (2):415-21 (2015)
18. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
    Long GV, et al.: N Engl J Med 371（20）: 1877-88（2014）
19. Improved overall survival in melanoma with combined dabrafenib and trametinib.
    Robert C, et al.: N Engl J Med 372（1）: 30-9（2015）